Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06271369 · ClinicalTrials.gov registry record
Real-World HRU and Costs in DLBCL Pts With Tisa-cel and Axi-cel, a Medicare Study.
A clinical trial, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- 613
- Enrollment target
NCT06271369 is a clinical trial that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 613 participants.
The verdict
NCT06271369 has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- 613 participants
- Enrollment target
Study Summary
This was a retrospective non-interventional cohort study design using the Centers for Medicare and Medicaid Services (CMS) 100% Medicare data (2015Q1-2020Q4). Eligible adult patients with r/r DLBCL who were treated with CAR-T therapy were identified from the CMS 100% Medicare data. Patients who received chimeric antigen receptor modified T cell (CAR-T) therapy were further classified into tisa-cel and axi-cel cohorts based on the type of CAR-T treatment received. The index date was defined as the date of tisa-cel or axi-cel therapy administration. Baseline period was defined as three months prior to the index date. Study period was defined from the index date to the end of health plan coverage based on insurance enrollment file or death, whichever occurred earlier.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 613 participants |
| Start Date | 2022-08-11 |
| Est. Completion | 2023-02-15 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06271369
The ClinicalTrials.gov registry entry for NCT06271369 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 613 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT06271369 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06271369 about?
NCT06271369 is a clinical study titled "Real-World HRU and Costs in DLBCL Pts With Tisa-cel and Axi-cel, a Medicare Study.". This was a retrospective non-interventional cohort study design using the Centers for Medicare and Medicaid Services (CMS) 100% Medicare data (2015Q1-2020Q4). Eligible adult patients with r/r DLBCL who were treated with CAR-T therapy were identified from the CMS 100% Medicare data. Patients who rec...
What is the current status of trial NCT06271369?
This trial is currently completed. The enrollment target is 613 participants. The study started on 2022-08-11. Estimated completion is 2023-02-15.
Who is sponsoring clinical trial NCT06271369?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.